A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients

PLoS One. 2017 Mar 24;12(3):e0173831. doi: 10.1371/journal.pone.0173831. eCollection 2017.

Abstract

Background: The mortality of dialysis patients is 10- to 100-fold higher than in the general population. Baseline serum PTH levels, and more recently, changes in serum PTH levels (ΔPTH) over time, have been associated to mortality in dialysis patients.

Methods: We explored the relationship between ΔPTH over 1 year with mortality over the next year in a prospective cohort of 115 prevalent hemodialysis patients from a single center that had median baseline iPTH levels within guideline recommendations.

Results: Median baseline iPTH levels were 205 (116.5, 400) pg/ml. ΔiPTH between baseline and 1 year was 85.2 ± 57.1 pg/ml. During the second year of follow-up, 27 patients died. ΔiPTH was significantly higher in patients who survived (+157.30 ± 25.82 pg/ml) than in those who died (+39.03 ± 60.95 pg/ml), while baseline iPTH values were not significantly different. The highest mortality (48%) was observed in patients with a decrease in ΔiPTH (ΔiPTH quartile 1, negative ΔiPTH) and the lowest (12%) mortality in quartile 3 ΔiPTH (ΔiPTH increase 101-300 pg/ml). In a logistic regression model, ΔiPTH was associated with mortality with an odds ratio (OR) of 0.998 (95% CI 0.996-0999, p = 0.038). In multivariable analysis, mortality risk was 73% and 88% lower for patients with ΔiPTH 0-100 pg/ml and 101-300 pg/ml, respectively, than for those with a decrease in ΔiPTH. In patients with a decrease in ΔiPTH, the OR for death was 4.131 (1.515-11.27)(p = 0.006).

Conclusions: In prevalent hemodialysis patients with median baseline iPTH values within the guideline recommended range, a decrease in ΔiPTH was associated with higher mortality. Further studies are required to understand the mechanisms and therapeutic implications of this observation that challenges current clinical practice.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood*
  • Prognosis
  • Prospective Studies
  • Renal Dialysis / mortality*

Substances

  • Parathyroid Hormone

Grants and funding

This work was supported by FIS PI16/01298, PI13/00047, PI16/02057, FEDER funds ISCIII-RETIC REDinREN RD12/0021, RD16/0009, FRIAT and Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CM) to A.O. The Spanish Ministerio de Economía y Competitividad (SAF-2014-60699-JIN) and Instituto de Salud Carlos III (“Sara borrell” CD14/00198 postdoctoral contract) supports R.V-B.